Login to Your Account

Informed-Consent Rules Can Add Glitch To Design Of Cancer Trials

By Randall Osborne

Monday, March 31, 2003

Genentech Inc., called the "premier" biotechnology firm by Elise Wang, analyst with Salomon Smith Barney - and Wang is hardly alone in her opinion - stands as one of the more closely watched companies in the biotechnology sector (maybe even the most watched of all), and a spate of news early this month focused even more attention on the firm.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription